Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ACTRN12625000619448) titled 'Efficacy of assigning treatment for participants with VEXAS syndrome with lenzilumab plus azacitidine' on June 13.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Efficacy
Primary Sponsor: South Australian Health & Medical Research Institute Ltd
Condition:
V - vacuoles are often seen in cells identified in bone marrow biopsies from patients with VEXAS syndrome.
E - E1 ubiquitin activating enzyme, encoded by the UBA1 gene which is mutated in patients
X - the UBA1 gene is located on the X...